Frederick Banting, a young surgeon from London, Ontario, conceived a groundbreaking hypothesis in 1920 regarding a pancreatic extract that could regulate blood sugar. He presented his innovative concept to Professor John Macleod, a prominent physiologist at the University of Toronto. Initially hesitant about the radical approach, Macleod eventually granted Banting laboratory facilities, ten experimental dogs, and the assistance of Charles Best, a medical student, for ten weeks during the summer of 1921. This crucial period marked the beginning of intensive research aimed at isolating an internal secretion from the pancreas, believed to be the missing component in diabetic patients.

The research commenced with Banting and Best meticulously ligating the pancreatic ducts of dogs, a technique intended to induce atrophy of the digestive enzyme-producing cells while preserving the hormone-secreting islets. After several weeks, they extracted a substance from the degenerated pancreases, which they initially termed "isletin." This crude extract was then administered to diabetic dogs, demonstrating a remarkable reduction in their elevated blood glucose levels and an improvement in their overall condition. The early experiments, though fraught with technical difficulties and inconsistencies in purity, provided compelling evidence that their pancreatic extract possessed potent anti-diabetic properties.

Despite early successes in animal trials, the extract's impurity posed significant challenges for human application. Professor Macleod then enlisted the expertise of James Collip, a biochemist, to refine the purification process. Collip's work was pivotal, leading to a more stable and less toxic preparation. The first human recipient was 14-year-old Leonard Thompson, critically ill with type 1 diabetes, who received the extract in January 1922. After an initial allergic reaction, a refined dose proved dramatically effective, lowering his blood sugar and alleviating his symptoms. This breakthrough, soon named "insulin," transformed Thompson's prognosis and offered hope to millions.

The immediate success of insulin led to a rapid scale-up in production. The University of Toronto licensed the patent for a nominal fee to ensure widespread accessibility, partnering with pharmaceutical companies like Eli Lilly and Company for mass manufacturing. Within a year, insulin became globally available, drastically improving the life expectancy and quality of life for individuals with diabetes, who previously faced a grim prognosis. In recognition of this monumental achievement, Banting and Macleod were awarded the Nobel Prize in Physiology or Medicine in 1923. They controversially shared their prize money with Best and Collip, acknowledging their indispensable contributions to the discovery.

Not Given